$119 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 33 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $5,390,466 | -38.8% | 250,370 | -23.4% | 4.54% | -20.6% |
| TSHA | Sell | TAYSHA GENE THERAPIES INC | $5,221,299 | -45.4% | 2,330,937 | -30.1% | 4.40% | -29.2% |
| RVMD | Sell | REVOLUTION MEDICINES INC | $5,161,730 | +11.4% | 133,000 | -7.5% | 4.35% | +44.4% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $4,345,000 | -47.7% | 27,500 | -57.1% | 3.66% | -32.2% |
| MRSN | Sell | MERSANA THERAPEUTICS INC | $3,342,630 | -65.5% | 1,663,000 | -23.2% | 2.82% | -55.3% |
| TERN | Sell | TERNS PHARMACEUTICALS INC | $2,514,797 | -17.6% | 369,280 | -20.6% | 2.12% | +6.9% |
| ORIC | Sell | ORIC PHARMACEUTICALS INC | $678,720 | -52.5% | 96,000 | -7.7% | 0.57% | -38.4% |
| Sell | LEAP THERAPEUTICS INC | $382,200 | -59.4% | 195,000 | -44.9% | 0.32% | -47.4% | |
| Sell | CELLECTAR BIOSCIENCES INC. | $176,250 | -69.1% | 70,500 | -50.9% | 0.15% | -60.1% | |
| ITCI | Exit | INTRA-CELLULAR THERAPIES INC. | $0 | – | -13,300 | -100.0% | -0.60% | – |
| RARE | Exit | ULTRAGENYX PHARMACEUTICAL INC | $0 | – | -20,000 | -100.0% | -0.61% | – |
| LYRA | Exit | LYRA THERAPEUTICS INC | $0 | – | -173,320 | -100.0% | -0.70% | – |
| Exit | VERASTEM INC | $0 | – | -207,095 | -100.0% | -1.59% | – | |
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -92,346 | -100.0% | -1.94% | – |
| Exit | HILLEVAX INC | $0 | – | -250,609 | -100.0% | -2.71% | – | |
| CLDX | Exit | CELLDEX THERAPEUTICS INC | $0 | – | -109,000 | -100.0% | -2.97% | – |
| Exit | DISC MEDICINE INC | $0 | – | -76,800 | -100.0% | -3.11% | – | |
| APLT | Exit | APPLIED THERAPEUTICS INC | $0 | – | -792,000 | -100.0% | -3.50% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| KURA ONCOLOGY INC. COMMON STOCK | 20 | Q2 2024 | 8.1% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| APELLIS PHARMACEUTICALS INC | 18 | Q4 2023 | 18.4% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.